Pbmc-derived Cik Cells
Pbmc-derived Cik Cells - Related Videos
02:26
A Technique to Generate a Human PBMC-Engrafted Humanized Xenograft Mouse Model
0 Views •
2025
This video demonstrates an assay to generate a humanized xenograft mouse model. An immunocompromised mouse is injected with cyclophosphamide to cause immune cell depletion. Patient-derived tumor cells mixed with human peripheral blood mononuclear cells (PBMCs) in a hydrogel are subcutaneously injected into the mouse, forming a tumor with infiltrating T cells.
05:35
CD Marker Recognition of Human Cytokine-Induced Killer Cells by Flow Cytometry
0 Views •
2025
In this video, we demonstrate a flow cytometry-based technique to determine the proportion of cytokine-induced killer T-cells, CIK cells, expanded from a peripheral blood mononuclear cell culture.
11:40
A Co-culture Method to Investigate the Crosstalk Between X-ray Irradiated Caco-2 Cells and PBMC
0 Views •
Cited by 7 •
2018
We present a protocol to investigate the crosstalk between X-ray-irradiated Caco-2 and peripheral blood mononuclear cells (PBMC). The protocol starts with Caco-2 irradiation and set-up of the co-culture with PBMC; subsequently, trans-epithelial electrical resistance is measured regularly over 48 h and western blot performed in both Caco-2 and PBMC.
11:56
Derivation of Human Embryonic Stem Cells by Immunosurgery
0 Views •
Cited by 12 •
2007
The ability of human embryonic stem cells to self-renew and differentiate into all cell types of the body suggests that they hold great promise for both medical applications and as a research tool for addressing fundamental questions in development and disease. Here, we provide a concise, step-by-step protocol for the derivation of human embryonic stem cells from embryos by immunosurgical isolation of the inner cell mass.
22:06
Derivation of Hematopoietic Stem Cells from Murine Embryonic Stem Cells
0 Views •
Cited by 7 •
2007
This protocol details the derivation of transplantable hematopoietic stem cells from mouse embryonic stem cells (ESC) and their subsequent injection into lethally irradiated recipient mice. Briefly, ESC are differentiated as embryoid bodies, which are then infected with retroviral HoxB4 and co-cultured with OP9 stromal cells and hematopoietic cytokines.
FAQs
Production uses a staged signaling strategy. Interferon-γ provides the priming signal, anti-CD3 supplies stimulation, and interleukin-2 supports subsequent expansion. Together, these inputs drive expansion of the starting PBMC population while yielding a heterogeneous effector-cell product rather than a single uniform lineage. This sequence is central to generating cells suitable for downstream antitumor studies.
CD3+CD56+ cells are important because they combine CD3 expression with CD56 expression and display natural killer-like, major histocompatibility complex-unrestricted cytotoxicity. This phenotype helps explain why the expanded population can act against tumor targets without requiring a matching tumor-specific antigen. Examining this subset can therefore connect cell composition with functional antitumor activity in cancer research experiments.
They can destroy tumor targets through cytotoxic granules and death-receptor pathways. Granules provide one direct means of delivering cytotoxic activity, while death-receptor signaling offers a separate route to target-cell elimination. Because these mechanisms do not depend on tumor-specific antigen matching, experiments can evaluate activity across a broad range of tumor targets rather than a single matched target.
Generation begins with peripheral blood mononuclear cells, followed by ex vivo interferon-γ priming, anti-CD3 stimulation, and interleukin-2-driven expansion. The resulting cells are then available as an expanded effector population for cancer research or immunotherapy studies. This workflow links the initial blood-derived material to the functional cell product evaluated in downstream experiments.
These cells are useful when a study needs to examine antitumor activity without restricting analysis to one tumor-specific antigen match. In cancer research, investigators can use them to study killing mechanisms, test combination treatments, and assess adoptive cell therapy strategies. Their broad target recognition makes them relevant for comparing how different experimental interventions influence immune-mediated tumor-cell destruction.
Ex vivo expansion creates an experimentally available population from the original PBMC starting material before researchers assess its antitumor behavior. This enables investigators to examine cytotoxicity, tumor-target recognition, combination-treatment effects, or adoptive cell therapy strategies using the generated effector cells rather than the unexpanded starting population directly.